Corrigendum to "Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study" [Eur. J. Cancer, vol. 205 (2024) 114119]

Affiliations

• ¹ Maisonneuve-Rosemont Hospital, Montreal, QC, Canada. Electronic address: [email protected].
• ² Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.
• ³ BC Cancer, Victoria, Victoria, BC, Canada.
• ⁴ McGill University Health Centre, Cedars Cancer Centre, Montreal, QC, Canada.
• ⁵ Ottawa Hospital, ON, Canada.
• ⁶ Centre Hospitalier Universitaire de Qu´ebec, Quebec, QC, Canada.
• ⁷ Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.
• ⁸ Tom Baker Cancer Center, Calgary, AB, Canada.
• ⁹ Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medical Oncology, Mount Sinai Hospital, Toronto, ON, Canada.
• ¹⁰ Yale University, New Haven, CT, USA.